| Elevated human epididymis protein 4 concentrations in chronic kidney disease B Nagy Jr, ZT Krasznai, H Balla, M Csobán, P Antal-Szalmás, Z Hernádi, ... Annals of clinical biochemistry 49 (4), 377-380, 2012 | 151 | 2012 |
| Survivin promoter polymorphism and cervical carcinogenesis AA Borbély, M Murvai, K Szarka, J Kónya, L Gergely, Z Hernádi, G Veress Journal of clinical pathology 60 (3), 303-306, 2007 | 100 | 2007 |
| Role of the Na+/Ca2+ exchanger in calcium homeostasis and human sperm motility regulation Z Krasznai, ZT Krasznai, M Morisawa, ZK Bazsáné, Z Hernádi, Z Fazekas, ... Cell motility and the cytoskeleton 63 (2), 66-76, 2006 | 70 | 2006 |
| Duration of HPV-associated risk for high-grade cervical intraepithelial neoplasia Z Hernádi, L Gazdag, K Szőke, T Sápy, ZT Krasznai, J Kónya European Journal of Obstetrics & Gynecology and Reproductive Biology 125 (1 …, 2006 | 56 | 2006 |
| Additional human papillomavirus types detected by the hybrid capture tube test among samples from women with cytological and colposcopical atypia J Kónya, G Veress, A Juhász, K Szarka, T Sápy, Z Hernádi, L Gergely Journal of clinical microbiology 38 (1), 408-411, 2000 | 45 | 2000 |
| Integration status of virus DNA and p53 codon 72 polymorphism in human papillomavirus type 16 positive cervical cancers. K Szarka, G Veress, A Juhasz, J Konya, T Sapy, G Soos, Z Hernadi, ... Anticancer research 20 (3B), 2161-2167, 2000 | 41 | 2000 |
| Correlation of human papillomavirus 16 and 18 with prognostic factors in invasive cervical neoplasias J Kónya, G Veress, Z Hernádi, G Soós, J Czeglédy, L Gergely Journal of medical virology 46 (1), 1-6, 1995 | 41 | 1995 |
| Role of human papillomavirus (HPV) testing in the follow-up of patients after treatment for cervical precancerous lesions Z Hernádi, K Szőke, T Sápy, ZT Krasznai, G Soós, G Veress, L Gergely, ... European Journal of Obstetrics & Gynecology and Reproductive Biology 118 (2 …, 2005 | 40 | 2005 |
| The prognostic significance of HPV-16 genome status of the lymph nodes, the integration status and p53 genotype in HPV-16 positive cervical cancer: a long term follow up Z Hernádi, K Szarka, T Sápy, Z Krasznai, G Veress, R Póka BJOG: an international journal of obstetrics and gynaecology 110 (2), 205-209, 2003 | 34 | 2003 |
| Randomised trial comparing combinations of cyclophosphamide and cisplatin without or with doxorubicin or 4′-epi-doxorubicin in the treatment of advanced ovarian cancer Z Hernadi, B Juhasz, R Poka, LG Lampé International Journal of Gynecology & Obstetrics 27 (2), 199-204, 1988 | 34 | 1988 |
| Moderate variation of the oncogenic potential among high‐risk human papillomavirus types in gynecologic patients with cervical abnormalities K Szőke, T Sápy, Z Krasznai, Z Hernádi, G Szládek, G Veress, J Dillner, ... Journal of medical virology 71 (4), 585-592, 2003 | 31 | 2003 |
| Quantitative and functional assay of MDR1/P170-mediated MDR in ascites cells of patients with ovarian cancer ZT Krasznai, E Friedländer, A Nagy, G Szabó, G Vereb, K Goda, ... Anticancer research 25 (2A), 1187-1192, 2005 | 30 | 2005 |
| Pgp inhibition by UIC2 antibody can be followed in vitro by using tumor-diagnostic radiotracers, 99mTc-MIBI and 18FDG ZT Krasznai, Á Tóth, P Mikecz, Z Fodor, G Szabó, L Galuska, Z Hernádi, ... European Journal of Pharmaceutical Sciences 41 (5), 665-669, 2010 | 26 | 2010 |
| Human papillomavirus type 18 E6* mRNA in primary tumors and pelvic lymph nodes of Hungarian patients with squamous cervical cancer J Czeglédy, M Evander, Z Hernadi, L Gergely, G Wadell International journal of cancer 56 (2), 182-186, 1994 | 26 | 1994 |
| Poor clinical outcome in early stage cervical cancer with human papillomavirus-18 positive lymph nodes T Sápy, Z Hernádi, J Kónya, L Lukácskó European Journal of Obstetrics & Gynecology and Reproductive Biology 90 (1 …, 2000 | 24 | 2000 |
| Biphasic accumulation kinetics of [99mTc]-hexakis-2-methoxyisobutyl isonitrile in tumour cells and its modulation by lipophilic P-glycoprotein ligands T Márián, L Balkay, G Szabó, ZT Krasznai, Z Hernádi, L Galuska, ... European journal of pharmaceutical sciences 25 (2-3), 201-209, 2005 | 23 | 2005 |
| Treatment patterns, health care utilization, and costs of ovarian cancer in Central and Eastern Europe using a Delphi panel based on a retrospective chart review K Kim, E Hernlund, Z Hernadi, J Révész, I Pete, A Szánthó, L Bodnar, ... International Journal of Gynecologic Cancer 23 (5), 2013 | 22 | 2013 |
| Phase II Clinical Evaluation of Etoposide (VP-16-213, Vepesid®) as a Second-Line Treatment in Ovarian Cancer: Results of the South-East European Oncology Group (SEEOG) Study S Eckhardt, Z Hernádi, L Thurzó, A Telekes, B Sopkova, Z Mechl, ... Oncology 47 (4), 289-295, 1990 | 22 | 1990 |
| Sequence variation of human papillomavirus type 31 long control region: phylogenetic and functional implications A Ferenczi, E Gyöngyösi, A Szalmas, Z Hernadi, Z Toth, J Konya, ... Journal of medical virology 85 (5), 852-859, 2013 | 20 | 2013 |
| Detection of human papillomavirus deoxyribonucleic acid in the female genital tract J Czeglédy, L Gergely, Z Hernádi, R Poka Medical microbiology and immunology 178, 309-314, 1989 | 20 | 1989 |
